Overview

Corporate Profile

T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, improves patient care and reduces the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx Instrument, T2Candida Panel and T2Bacteria Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including detection of additional species and antibiotic resistance markers of sepsis pathogens and tests for Lyme disease. For more information, please visit www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.45
Change (%)0.00 (0.00%)
Volume0
Data as of 08/17/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
08/06/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on August 1, 2018 it issued inducement awards to two new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides... 
Printer Friendly Version
08/02/18T2 Biosystems Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Quarterly Product Revenue Up 71% Year-Over-Year Launched the Recently FDA Cleared T2Bacteria Panel, the Flagship Product in the T2Direct Diagnostics Portfolio Reiterates 2018 Financial Guidance, Including Increase to Lower End of Revenue Guidance Range LEXINGTON, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced to... 
Printer Friendly Version
07/24/18T2 Biosystems to Participate in Two Upcoming Conferences
LEXINGTON, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to participate in two upcoming investor conferences. The first conference is the 3rd Annual Needham MedTech 1x1 Conference, which is being held August 7 in Boston. This conferen... 
Printer Friendly Version
07/20/18T2 Biosystems Announces 2018 Second Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 second quarter financial and operational results after the market closes on Thursday, August 2, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Easte... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Matthew Clawson, W2O Group 
mclawson@w2ogroup.com
(949) 370-8500

Data provided by Nasdaq. Minimum 15 minutes delayed.